US8053191B2
(en)
|
2006-08-31 |
2011-11-08 |
Westend Asset Clearinghouse Company, Llc |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
IL280133B2
(en)
|
2010-11-12 |
2023-04-01 |
Gen9 Inc |
Methods and devices for nucleic acids synthesis
|
US10457935B2
(en)
|
2010-11-12 |
2019-10-29 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
US11560585B2
(en)
|
2011-01-31 |
2023-01-24 |
Roche Sequencing Solutions, Inc. |
Methods of identifying multiple epitopes in cells
|
WO2012106385A2
(en)
|
2011-01-31 |
2012-08-09 |
Apprise Bio, Inc. |
Methods of identifying multiple epitopes in cells
|
EP3613852A3
(en)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
ES2737957T3
(en)
|
2011-08-26 |
2020-01-17 |
Gen9 Inc |
Compositions and methods for high fidelity nucleic acid assembly
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US9637739B2
(en)
*
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
CN104603286B
(en)
|
2012-04-24 |
2020-07-31 |
Gen9股份有限公司 |
Method for sorting nucleic acids and multiplex preparations in vitro cloning
|
SG10201702445TA
(en)
|
2012-04-25 |
2017-04-27 |
Regeneron Pharma |
Nuclease-mediated targeting with large targeting vectors
|
EA038924B1
(en)
|
2012-05-25 |
2021-11-10 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
BR112014031891A2
(en)
|
2012-06-19 |
2017-08-01 |
Univ Minnesota |
genetic targeting in plants using DNA viruses
|
LT2864531T
(en)
|
2012-06-25 |
2019-03-12 |
Gen9, Inc. |
Methods for nucleic acid assembly and high throughput sequencing
|
CN105441440B
(en)
|
2012-10-23 |
2020-12-15 |
基因工具股份有限公司 |
Composition for cleaving target DNA comprising guide RNA specific for target DNA and CAS protein-encoding nucleic acid or CAS protein, and use thereof
|
KR102531576B1
(en)
*
|
2012-12-06 |
2023-05-11 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Crispr-based genome modification and regulation
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
US20140310830A1
(en)
*
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
CN113528577A
(en)
|
2012-12-12 |
2021-10-22 |
布罗德研究所有限公司 |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
ES2576128T3
(en)
|
2012-12-12 |
2016-07-05 |
The Broad Institute, Inc. |
Modification by genetic technology and optimization of systems, methods and compositions for the manipulation of sequences with functional domains
|
EP4234696A3
(en)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
JP6552965B2
(en)
|
2012-12-12 |
2019-07-31 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
ES2701749T3
(en)
|
2012-12-12 |
2019-02-25 |
Broad Inst Inc |
Methods, models, systems and apparatus to identify target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and transmit results thereof
|
ES2883590T3
(en)
|
2012-12-12 |
2021-12-09 |
Broad Inst Inc |
Supply, modification and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
EP2932421A1
(en)
*
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
RU2766685C2
(en)
*
|
2012-12-17 |
2022-03-15 |
Президент Энд Фэллоуз Оф Харвард Коллидж |
Rna-guided human genome engineering
|
AU2014207618A1
(en)
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
WO2014130706A1
(en)
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
US10138509B2
(en)
|
2013-03-12 |
2018-11-27 |
President And Fellows Of Harvard College |
Method for generating a three-dimensional nucleic acid containing matrix
|
AU2014235794A1
(en)
*
|
2013-03-14 |
2015-10-22 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
CN112301024A
(en)
|
2013-03-15 |
2021-02-02 |
通用医疗公司 |
Increasing specificity of RNA-guided genome editing using RNA-guided FokI nuclease (RFN)
|
MX2015011985A
(en)
*
|
2013-03-15 |
2016-04-07 |
Univ Minnesota |
Engineering plant genomes using crispr/cas systems.
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
CN115261411A
(en)
|
2013-04-04 |
2022-11-01 |
哈佛学院校长同事会 |
Therapeutic uses of genome editing with CRISPR/Cas systems
|
LT3456831T
(en)
|
2013-04-16 |
2021-09-10 |
Regeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
CA2910489A1
(en)
*
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
US11414695B2
(en)
|
2013-05-29 |
2022-08-16 |
Agilent Technologies, Inc. |
Nucleic acid enrichment using Cas9
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
CN105451778B
(en)
*
|
2013-06-04 |
2021-08-03 |
哈佛大学校长及研究员协会 |
RNA-guided transcriptional regulation
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
RU2716420C2
(en)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Delivery and use of systems of crispr-cas, vectors and compositions for targeted action and therapy in liver
|
CA2915834A1
(en)
|
2013-06-17 |
2014-12-24 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
CN105793425B
(en)
|
2013-06-17 |
2021-10-26 |
布罗德研究所有限公司 |
Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components
|
CN105492611A
(en)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
Optimized CRISPR-CAS double nickase systems, methods and compositions for sequence manipulation
|
EP3019595A4
(en)
|
2013-07-09 |
2016-11-30 |
|
Therapeutic uses of genome editing with crispr/cas systems
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
US20150044772A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
Crispr/cas system-based novel fusion protein and its applications in genome editing
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
EP3611268A1
(en)
|
2013-08-22 |
2020-02-19 |
E. I. du Pont de Nemours and Company |
Plant genome modification using guide rna/cas endonuclease systems and methods of use
|
EA037850B1
(en)
|
2013-08-29 |
2021-05-27 |
Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн |
Methods and compositions for rna-guided treatment of hiv infection
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
WO2015040402A1
(en)
|
2013-09-18 |
2015-03-26 |
Kymab Limited |
Methods. cells & organisms
|
CA2926094C
(en)
|
2013-10-17 |
2024-04-02 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
WO2015066119A1
(en)
|
2013-10-30 |
2015-05-07 |
North Carolina State University |
Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
|
DK3066201T3
(en)
|
2013-11-07 |
2018-06-06 |
Editas Medicine Inc |
CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
ES2700596T3
(en)
|
2013-12-11 |
2019-02-18 |
Regeneron Pharma |
Methods and compositions for the targeted modification of a genome
|
WO2015088643A1
(en)
|
2013-12-11 |
2015-06-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
CA2932439A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
AU2014361781B2
(en)
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
JP6712948B2
(en)
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Compositions and methods of using the CRISPR-cas system in nucleotide repeat disorders
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
EP3690044B1
(en)
|
2014-02-11 |
2024-01-10 |
The Regents of the University of Colorado, a body corporate |
Crispr enabled multiplexed genome engineering
|
EP3114227B1
(en)
|
2014-03-05 |
2021-07-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
EP3553176A1
(en)
|
2014-03-10 |
2019-10-16 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
EP3981876A1
(en)
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
CA2944978C
(en)
|
2014-04-08 |
2024-02-13 |
North Carolina State University |
Methods and compositions for rna-directed repression of transcription using crispr-associated genes
|
US10066241B2
(en)
|
2014-05-30 |
2018-09-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
ES2784754T3
(en)
|
2014-06-06 |
2020-09-30 |
Regeneron Pharma |
Methods and compositions to modify a target locus
|
SI3354732T1
(en)
|
2014-06-23 |
2020-07-31 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated dna assembly
|
SI3161128T1
(en)
|
2014-06-26 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
CN106687594A
(en)
|
2014-07-11 |
2017-05-17 |
纳幕尔杜邦公司 |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
WO2016011080A2
(en)
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
Crispr/cas transcriptional modulation
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
CA2958292A1
(en)
|
2014-08-19 |
2016-02-25 |
President And Fellows Of Harvard College |
Rna-guided systems for probing and mapping of nucleic acids
|
US9970030B2
(en)
*
|
2014-08-27 |
2018-05-15 |
Caribou Biosciences, Inc. |
Methods for increasing CAS9-mediated engineering efficiency
|
WO2016033298A1
(en)
|
2014-08-28 |
2016-03-03 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
US10570418B2
(en)
|
2014-09-02 |
2020-02-25 |
The Regents Of The University Of California |
Methods and compositions for RNA-directed target DNA modification
|
WO2016040594A1
(en)
*
|
2014-09-10 |
2016-03-17 |
The Regents Of The University Of California |
Reconstruction of ancestral cells by enzymatic recording
|
CA2956487A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
CN113930455A
(en)
*
|
2014-10-09 |
2022-01-14 |
生命技术公司 |
CRISPR oligonucleotides and gene clips
|
EP3561052A1
(en)
|
2014-10-15 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
WO2016065364A1
(en)
*
|
2014-10-24 |
2016-04-28 |
Life Technologies Corporation |
Compositions and methods for enhancing homologous recombination
|
WO2016065341A1
(en)
|
2014-10-24 |
2016-04-28 |
Avectas Limited |
Delivery across cell plasma membranes
|
WO2016073990A2
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
RS58893B1
(en)
|
2014-11-21 |
2019-08-30 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification using paired guide rnas
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
CN105695485B
(en)
*
|
2014-11-27 |
2020-02-21 |
中国科学院上海生命科学研究院 |
Cas9 encoding gene for filamentous fungus Crispr-Cas system and application thereof
|
CN107250148B
(en)
|
2014-12-03 |
2021-04-16 |
安捷伦科技有限公司 |
Guide RNAs with chemical modifications
|
US9888673B2
(en)
|
2014-12-10 |
2018-02-13 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
EP3234111A1
(en)
|
2014-12-19 |
2017-10-25 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
CN107208113A
(en)
|
2014-12-19 |
2017-09-26 |
瑞泽恩制药公司 |
Method and composition for carrying out targeting genetic modification by the multiple targeting of single step
|
EP3234602B1
(en)
*
|
2014-12-19 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Methods for identifying multiple epitopes in selected sub-populations of cells
|
US11208638B2
(en)
|
2015-01-12 |
2021-12-28 |
The Regents Of The University Of California |
Heterodimeric Cas9 and methods of use thereof
|
US11180792B2
(en)
|
2015-01-28 |
2021-11-23 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
WO2016120480A1
(en)
*
|
2015-01-29 |
2016-08-04 |
Meiogenix |
Method for inducing targeted meiotic recombinations
|
WO2016149422A1
(en)
*
|
2015-03-16 |
2016-09-22 |
The Broad Institute, Inc. |
Encoding of dna vector identity via iterative hybridization detection of a barcode transcript
|
WO2016160389A1
(en)
|
2015-03-27 |
2016-10-06 |
E I Du Pont De Nemours And Company |
Soybean u6 small nuclear rna gene promoters and their use in constitutive expression of small rna genes in plants
|
KR102648489B1
(en)
|
2015-04-06 |
2024-03-15 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Chemically modified guide RNA for CRISPR/CAS-mediated gene regulation
|
AU2016253150B2
(en)
|
2015-04-24 |
2022-04-21 |
Editas Medicine, Inc. |
Evaluation of Cas9 molecule/guide RNA molecule complexes
|
AU2016261358B2
(en)
|
2015-05-11 |
2021-09-16 |
Editas Medicine, Inc. |
Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
|
EP3294879A4
(en)
*
|
2015-05-14 |
2019-02-20 |
University of Southern California |
Optimized gene editing utilizing a recombinant endonuclease system
|
EP3324999A1
(en)
|
2015-05-29 |
2018-05-30 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
KR102451796B1
(en)
|
2015-05-29 |
2022-10-06 |
노쓰 캐롤라이나 스테이트 유니버시티 |
Methods for screening bacteria, archaea, algae and yeast using CRISPR nucleic acids
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
AU2016276702B2
(en)
|
2015-06-09 |
2022-07-28 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for improving transplantation
|
EP3307872B1
(en)
|
2015-06-15 |
2023-09-27 |
North Carolina State University |
Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
CN108290933A
(en)
|
2015-06-18 |
2018-07-17 |
布罗德研究所有限公司 |
Reduce the CRISPR enzyme mutants of undershooting-effect
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
JP2018519811A
(en)
|
2015-06-29 |
2018-07-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
WO2017011721A1
(en)
|
2015-07-15 |
2017-01-19 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
WO2017023803A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
EP3331906A1
(en)
|
2015-08-06 |
2018-06-13 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
CA2996888A1
(en)
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
WO2017040511A1
(en)
|
2015-08-31 |
2017-03-09 |
Agilent Technologies, Inc. |
Compounds and methods for crispr/cas-based genome editing by homologous recombination
|
WO2017040786A1
(en)
*
|
2015-09-04 |
2017-03-09 |
Massachusetts Institute Of Technology |
Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells
|
WO2017049129A2
(en)
*
|
2015-09-18 |
2017-03-23 |
President And Fellows Of Harvard College |
Methods of making guide rna
|
WO2017053312A1
(en)
*
|
2015-09-21 |
2017-03-30 |
The Regents Of The University Of California |
Compositions and methods for target nucleic acid modification
|
EP3786294A1
(en)
|
2015-09-24 |
2021-03-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
MX2018004263A
(en)
*
|
2015-10-08 |
2019-08-16 |
Harvard College |
Multiplexed genome editing.
|
JP7109784B2
(en)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Evolved Cas9 protein for gene editing
|
WO2017074962A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Brandeis University |
Modified cas9 compositions and methods of use
|
AU2016349288A1
(en)
|
2015-11-03 |
2018-05-31 |
President And Fellows Of Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
BR112018009515A2
(en)
|
2015-11-11 |
2018-11-06 |
Univ Minnesota |
biocontainment / biocontrol system and methods
|
CN106893739A
(en)
|
2015-11-17 |
2017-06-27 |
香港中文大学 |
For the new method and system of target gene operation
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
WO2017112620A1
(en)
|
2015-12-22 |
2017-06-29 |
North Carolina State University |
Methods and compositions for delivery of crispr based antimicrobials
|
US11827899B2
(en)
|
2015-12-30 |
2023-11-28 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
JP7012645B2
(en)
|
2016-01-11 |
2022-01-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Chimeric proteins and immunotherapeutic methods
|
EA201891619A1
(en)
|
2016-01-11 |
2019-02-28 |
Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити |
CHEMERAL PROTEINS AND METHODS OF REGULATING GENE EXPRESSION
|
CN105624187A
(en)
*
|
2016-02-17 |
2016-06-01 |
天津大学 |
Site-directed mutation method for genomes of saccharomyces cerevisiae
|
WO2017143071A1
(en)
|
2016-02-18 |
2017-08-24 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
WO2017151444A1
(en)
|
2016-02-29 |
2017-09-08 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
|
EP3429567B1
(en)
|
2016-03-16 |
2024-01-10 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
AU2017238512B2
(en)
*
|
2016-03-23 |
2022-12-08 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
US11597924B2
(en)
|
2016-03-25 |
2023-03-07 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
EP3433364A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
AU2017253107B2
(en)
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
CPF1 complexes with reduced indel activity
|
KR102424476B1
(en)
|
2016-04-19 |
2022-07-25 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Novel CRISPR Enzymes and Systems
|
WO2017189525A1
(en)
|
2016-04-25 |
2017-11-02 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
CN109415756B
(en)
*
|
2016-04-28 |
2022-08-09 |
延世大学校产学协力团 |
Methods for in vivo assessment of the activity of RNA-guided nucleases in a high-throughput manner
|
EP3457840B1
(en)
|
2016-05-20 |
2024-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide rnas
|
EP3272867B1
(en)
|
2016-06-02 |
2019-09-25 |
Sigma Aldrich Co. LLC |
Using programmable dna binding proteins to enhance targeted genome modification
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
CN109688820B
(en)
|
2016-06-24 |
2023-01-10 |
科罗拉多州立大学董事会(法人团体) |
Methods for generating barcoded combinatorial libraries
|
CN109963564B
(en)
*
|
2016-07-27 |
2022-08-12 |
利兰斯坦福初级大学董事会 |
Disaggregated cell-penetrating complexes for nucleic acid delivery
|
DK3491130T3
(en)
|
2016-07-28 |
2022-10-24 |
Dsm Ip Assets Bv |
ASSEMBLY SYSTEM FOR A EUKARYOTIC CELL
|
KR20190041476A
(en)
|
2016-07-29 |
2019-04-22 |
리제너론 파마슈티칼스 인코포레이티드 |
A mouse containing a mutation inducing the expression of C-truncated fibrilin-1
|
BR112019001887A2
(en)
|
2016-08-02 |
2019-07-09 |
Editas Medicine Inc |
compositions and methods for treating cep290-associated disease
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
AU2017324462B2
(en)
*
|
2016-09-07 |
2024-03-21 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
JP2019532644A
(en)
|
2016-09-30 |
2019-11-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
RNA-induced nucleic acid modifying enzyme and method of using the same
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
CA3040481A1
(en)
|
2016-10-14 |
2018-04-19 |
The General Hospital Corporation |
Epigenetically regulated site-specific nucleases
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
GB2573406B
(en)
|
2016-10-18 |
2021-11-10 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
US11229662B2
(en)
|
2016-11-15 |
2022-01-25 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
CN110582302A
(en)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
Compositions and methods for nucleic acid and/or protein payload delivery
|
WO2018115973A2
(en)
|
2016-12-22 |
2018-06-28 |
Avectas Limited |
Vector-free intracellular delivery by reversible permeabilisation
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
JP7219972B2
(en)
|
2017-01-05 |
2023-02-09 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
DNA double-strand break-independent targeted gene editing platform and its applications
|
MX2019008675A
(en)
|
2017-01-23 |
2019-09-18 |
Regeneron Pharma |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof.
|
TW201839136A
(en)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
KR20190127797A
(en)
|
2017-03-10 |
2019-11-13 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Cytosine to Guanine Base Editing Agent
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
WO2018191520A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
EP3612232A1
(en)
|
2017-04-21 |
2020-02-26 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
CN110799525A
(en)
|
2017-04-21 |
2020-02-14 |
通用医疗公司 |
Variants of CPF1(CAS12a) with altered PAM specificity
|
EP3615672A1
(en)
|
2017-04-28 |
2020-03-04 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
WO2018204777A2
(en)
|
2017-05-05 |
2018-11-08 |
The Broad Institute, Inc. |
Methods for identification and modification of lncrna associated with target genotypes and phenotypes
|
WO2018209014A1
(en)
|
2017-05-10 |
2018-11-15 |
Regents Of The University Of Minnesota |
Programmable transcription factors and methods
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
WO2018218166A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
WO2018226880A1
(en)
|
2017-06-06 |
2018-12-13 |
Zymergen Inc. |
A htp genomic engineering platform for improving escherichia coli
|
EP3635112A2
(en)
|
2017-06-06 |
2020-04-15 |
Zymergen, Inc. |
A htp genomic engineering platform for improving fungal strains
|
WO2018225807A1
(en)
*
|
2017-06-07 |
2018-12-13 |
国立大学法人東京大学 |
Gene therapy for granular corneal dystrophy
|
CN110997908A
(en)
|
2017-06-09 |
2020-04-10 |
爱迪塔斯医药公司 |
Engineered CAS9 nucleases
|
CA3067382A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
Adeno-associated viral vectors for gene therapy
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
MX2020001178A
(en)
|
2017-07-31 |
2020-09-25 |
Regeneron Pharma |
Cas-transgenic mouse embryonic stem cells and mice and uses thereof.
|
CN110891419A
(en)
|
2017-07-31 |
2020-03-17 |
瑞泽恩制药公司 |
Evaluation of CRISPR/CAS-induced in vivo recombination with exogenous donor nucleic acids
|
JP2020533957A
(en)
|
2017-07-31 |
2020-11-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
CRISPR Reporter Non-Human Animals and Their Use
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
CN111163633B
(en)
|
2017-09-29 |
2022-09-09 |
瑞泽恩制药公司 |
Non-human animals comprising humanized TTR loci and methods of use thereof
|
BR112020006256A2
(en)
|
2017-09-29 |
2020-10-20 |
Intellia Therapeutics, Inc. |
in vitro method of administering mrna using lipid nanoparticles
|
JP2021500863A
(en)
|
2017-09-29 |
2021-01-14 |
インテリア セラピューティクス,インコーポレイテッド |
Polynucleotides, compositions and methods for genome editing
|
EP3688162B1
(en)
|
2017-09-29 |
2024-03-06 |
Intellia Therapeutics, Inc. |
Formulations
|
EP3688161A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
BR112020008201A2
(en)
|
2017-10-27 |
2020-10-06 |
The Regents Of The University Of California |
target replacement of endogenous t cell receptors
|
CA3082643A1
(en)
|
2017-11-14 |
2019-05-23 |
The Schepens Eye Research Institute, Inc. |
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
US20200362366A1
(en)
|
2018-01-12 |
2020-11-19 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
CA3089331A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
GB2587970B
(en)
|
2018-04-19 |
2023-02-08 |
Univ California |
Compositions and methods for gene editing
|
EP3794130A4
(en)
|
2018-05-16 |
2022-07-27 |
Synthego Corporation |
Methods and systems for guide rna design and use
|
EP3802779A1
(en)
|
2018-06-01 |
2021-04-14 |
Avectas Limited |
Cell engineering platform
|
EP3821012A4
(en)
|
2018-07-13 |
2022-04-20 |
The Regents of The University of California |
Retrotransposon-based delivery vehicle and methods of use thereof
|
AU2019313348A1
(en)
|
2018-07-31 |
2021-03-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for hydroxyacid oxidase 1 (HAO1) gene editing for treating primary hyperoxaluria type 1 (PH1)
|
EP3830256A2
(en)
|
2018-07-31 |
2021-06-09 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
CN110678553B
(en)
*
|
2018-08-21 |
2023-08-11 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
Method for genome editing in mammalian stem cells
|
BR112021005718A2
(en)
|
2018-09-28 |
2021-06-22 |
Intellia Therapeutics, Inc. |
compositions and methods for editing lactate dehydrogenase (ldha) genes
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
SG11202103571XA
(en)
|
2018-10-16 |
2021-05-28 |
Intellia Therapeutics Inc |
Compositions and methods for immunotherapy
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
EP3874037A4
(en)
|
2018-10-31 |
2021-12-15 |
Zymergen, Inc. |
Multiplexed deterministic assembly of dna libraries
|
US20220010321A1
(en)
*
|
2018-11-01 |
2022-01-13 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
KR20200071198A
(en)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Development of new adoptive T cell immunotherapy by modification of Nrf2 expression
|
BR112021011372A2
(en)
|
2018-12-14 |
2021-08-31 |
Pioneer Hi-Bred International, Inc. |
NEW CRISPR-CAS SYSTEMS FOR GENOME EDITING
|
KR20210105914A
(en)
|
2018-12-20 |
2021-08-27 |
리제너론 파마슈티칼스 인코포레이티드 |
Nuclease-mediated repeat expansion
|
EP3911746A1
(en)
|
2019-01-14 |
2021-11-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
EP3921417A4
(en)
|
2019-02-04 |
2022-11-09 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
MX2021010559A
(en)
|
2019-03-07 |
2021-12-15 |
Univ California |
Crispr-cas effector polypeptides and methods of use thereof.
|
CA3129871A1
(en)
|
2019-03-08 |
2020-09-17 |
Zymergen Inc. |
Iterative genome editing in microbes
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
EP3769090B1
(en)
|
2019-03-18 |
2023-11-15 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
KR20210141522A
(en)
|
2019-03-18 |
2021-11-23 |
리제너론 파마슈티칼스 인코포레이티드 |
CRISPR/Cas Screening Platform to Identify Genetic Modifiers of Tau Seeding or Aggregation
|
MX2021011426A
(en)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences.
|
EP3946285A1
(en)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof
|
MX2021011565A
(en)
|
2019-03-28 |
2021-11-12 |
Intellia Therapeutics Inc |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent.
|
CN113993994A
(en)
|
2019-03-28 |
2022-01-28 |
因特利亚治疗公司 |
Polynucleotides, compositions and methods for polypeptide expression
|
JP2022527809A
(en)
|
2019-04-03 |
2022-06-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Methods and compositions for inserting antibody coding sequences into safe harbor loci
|
SG11202108454RA
(en)
|
2019-04-04 |
2021-09-29 |
Regeneron Pharma |
Non-human animals comprising a humanized coagulation factor 12 locus
|
JP7065260B2
(en)
|
2019-04-04 |
2022-05-11 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Methods for Scarless Introduction of Targeted Modifications to Targeting Vectors
|
EP3801011A1
(en)
|
2019-06-04 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
CN113939595A
(en)
|
2019-06-07 |
2022-01-14 |
瑞泽恩制药公司 |
Non-human animals including humanized albumin loci
|
AU2020290509A1
(en)
|
2019-06-14 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
EP4022057A1
(en)
|
2019-08-27 |
2022-07-06 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive dna
|
JP2022548031A
(en)
|
2019-09-13 |
2022-11-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Transcriptional regulation in animals using the CRISPR/CAS system delivered by lipid nanoparticles
|
CA3151563A1
(en)
|
2019-09-20 |
2021-03-25 |
Feng Zhang |
Novel type vi crispr enzymes and systems
|
WO2021092513A1
(en)
|
2019-11-08 |
2021-05-14 |
Regeneron Pharmaceuticals, Inc. |
Crispr and aav strategies for x-linked juvenile retinoschisis therapy
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
CN114945273A
(en)
|
2019-11-29 |
2022-08-26 |
巴斯夫欧洲公司 |
Increasing the resistance of plants against fungal infections
|
CA3161898A1
(en)
|
2019-12-19 |
2021-06-24 |
Basf Se |
Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals
|
EP4077658A1
(en)
|
2019-12-20 |
2022-10-26 |
Basf Se |
Decreasing toxicity of terpenes and increasing the production potential in micro-organisms
|
US11060141B1
(en)
|
2019-12-23 |
2021-07-13 |
Stilla Technologies |
Multiplex drop-off digital polymerase chain reaction methods
|
US11965161B2
(en)
|
2020-03-04 |
2024-04-23 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for sensitization of tumor cells to immune therapy
|
WO2021191678A1
(en)
|
2020-03-23 |
2021-09-30 |
Avectas Limited |
Engineering of dendritic cells for generation of vaccines against sars-cov-2
|
WO2021195079A1
(en)
|
2020-03-23 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
US20210319851A1
(en)
|
2020-04-03 |
2021-10-14 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
JP2023522848A
(en)
|
2020-04-08 |
2023-06-01 |
アストラゼネカ・アクチエボラーグ |
Compositions and methods for improved site-specific modification
|
JP2023524666A
(en)
|
2020-04-28 |
2023-06-13 |
インテリア セラピューティクス,インコーポレイテッド |
Methods of in vitro cell delivery
|
IL297761A
(en)
|
2020-05-08 |
2022-12-01 |
Broad Inst Inc |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
US20230235315A1
(en)
|
2020-07-10 |
2023-07-27 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
US20220096606A1
(en)
|
2020-09-09 |
2022-03-31 |
Vertex Pharmaceuticals Incorporated |
Compositions and Methods for Treatment of Duchenne Muscular Dystrophy
|
US10947552B1
(en)
|
2020-09-30 |
2021-03-16 |
Alpine Roads, Inc. |
Recombinant fusion proteins for producing milk proteins in plants
|
EP4222167A1
(en)
|
2020-09-30 |
2023-08-09 |
Nobell Foods, Inc. |
Recombinant milk proteins and food compositions comprising the same
|
US10894812B1
(en)
|
2020-09-30 |
2021-01-19 |
Alpine Roads, Inc. |
Recombinant milk proteins
|
US20220145293A1
(en)
|
2020-10-21 |
2022-05-12 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
|
WO2022098933A1
(en)
|
2020-11-06 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
US20240002839A1
(en)
|
2020-12-02 |
2024-01-04 |
Decibel Therapeutics, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
CR20230303A
(en)
|
2020-12-11 |
2023-09-01 |
Intellia Therapeutics Inc |
Compositions and methods for reducing mhc class ii in a cell
|
CR20230320A
(en)
|
2020-12-23 |
2023-10-23 |
Intellia Therapeutics Inc |
Compositions and methods for reducing hla-a in a cell
|
CR20230321A
(en)
|
2020-12-23 |
2023-09-12 |
Intellia Therapeutics Inc |
Compositions and methods for genetically modifying ciita in a cell
|
CA3207144A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
CN117203319A
(en)
|
2021-02-01 |
2023-12-08 |
阿维塔斯有限公司 |
Delivery platform
|
WO2022170193A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
JP2024505678A
(en)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス,インコーポレイテッド |
Lymphocyte activation gene 3 (LAG3) compositions and methods for immunotherapy
|
EP4288525A1
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
Natural killer cell receptor 2b4 compositions and methods for immunotherapy
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
EP4298222A1
(en)
|
2021-02-26 |
2024-01-03 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
|
JP2024513087A
(en)
|
2021-04-07 |
2024-03-21 |
アストラゼネカ・アクチエボラーグ |
Compositions and methods for site-specific modification
|
US20220331361A1
(en)
*
|
2021-04-07 |
2022-10-20 |
Century Therapeutics, Inc. |
Gene transfer vectors and methods of engineering cells
|
AU2022258733A1
(en)
|
2021-04-17 |
2023-11-30 |
Intellia Therapeutics, Inc. |
Inhibitors of dna-dependent protein kinase and compositions and uses thereof
|
CA3216877A1
(en)
|
2021-04-17 |
2022-10-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle compositions
|
IL307741A
(en)
|
2021-04-17 |
2023-12-01 |
Intellia Therapeutics Inc |
Lipid nanoparticle compositions
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
WO2022240846A1
(en)
|
2021-05-10 |
2022-11-17 |
Sqz Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
EP4347826A1
(en)
|
2021-06-02 |
2024-04-10 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
WO2023028471A1
(en)
|
2021-08-24 |
2023-03-02 |
Intellia Therapeutics, Inc. |
Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
AU2022343300A1
(en)
|
2021-09-10 |
2024-04-18 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
WO2023064924A1
(en)
|
2021-10-14 |
2023-04-20 |
Codiak Biosciences, Inc. |
Modified producer cells for extracellular vesicle production
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
WO2023081689A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023081200A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150623A2
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
WO2023172927A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|